NCT06398613

Preoperative PSMA PET/CT as Triage for ePLND in Patients Scheduled for RALP (PrePSMA)

Name: Clinical Trial NCT06398613
Creator: Oslo University Hospital
Keywords: Prostate Cancer, PSMA PET/CT, diagnostic test, clinical trial, Norway

Preoperative PSMA PET/CT as Triage for Extended Pelvic Lymph Node Dissection (ePLND) in Patients Scheduled for Robot-Assisted Laparoscopic Radical Prostatectomy (RALP)

Oslo University Hospital·ClinicalTrials.gov·diagnostic testRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Prostate Cancer
Drug/Device/Intervention: PSMA PET/CT
Study type: Interventional
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Oslo University Hospital
Location: Oslo, Norway

Timeline & enrollment

Phase: N/A
Start date: Apr 26, 2024
End date: Dec 31, 2029
Enrollment: 600 participants

Primary outcome

Difference between Arm A and Arm B in biochemical recurrence (BCR) rate between groups within 2 years after initiation of RALP

Summary

Extended pelvic lymph node dissection (ePLND) is considered the gold standard for nodal staging in men with prostate cancer (PCa). The aim of this project is to determine if preoperative prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomograpy (CT) can safely replace ePLND as a staging method in PCa patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP).

ICD-10 classifications

Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06398613
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06398613 through Pure Global AI's free database. This phase not specified trial is sponsored by Oslo University Hospital and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.